All In Biotech

Drug Trial Radar · NCT07731685

A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of VC004 Capsules for Pain in Bone Metastases

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

26

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Dec 30, 2027

Study completion Dec 30, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled Phase Ib study evaluating the safety and efficacy of VC004 capsules for the relief of moderate-to-severe pain associated with bone metastases

Conditions

  • Pain in Bone Metastases

Interventions

  • VC004 low doseDrug

    VC004 low dose BID

  • VC004 high doseDrug

    VC004 high dose BID

  • VC004 placeboDrug

    VC004 placebo BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the daily average pain intensity Numeric Rating Scale (NRS) scoreTime frame: At Week 1, Week 2 and Week 4

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Zhongda Hospital,Affiliated to Southeast University

    Nanjing, Jiangsu, China

  • Zhongda Hospital,Affiliated to Southeast University

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.